271 related articles for article (PubMed ID: 8790499)
1. Choice of serum markers in antenatal screening for Down's syndrome.
Wald NJ; Watt HC
J Med Screen; 1994 Apr; 1(2):117-20. PubMed ID: 8790499
[No Abstract] [Full Text] [Related]
2. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
Piggott M; Wilkinson P; Bennett J
J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
[TBL] [Abstract][Full Text] [Related]
3. First-trimester or second-trimester screening, or both, for Down's syndrome.
Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
[TBL] [Abstract][Full Text] [Related]
4. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
[TBL] [Abstract][Full Text] [Related]
5. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
[TBL] [Abstract][Full Text] [Related]
6. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
7. Detection of pregnancies with trisomy 18 in screening programmes for Down's syndrome.
Hackshaw AK; Kennard A; Wald NJ
J Med Screen; 1995; 2(4):228-9. PubMed ID: 8719154
[No Abstract] [Full Text] [Related]
8. [Evaluation of Down's syndrome screening methods using maternal serum biochemistry in the second trimester pregnancy].
Yu DY; Fu P; Zhang ZH; Wang F; Han MY; Ren HY; Zhao W; Zhang K; Li S; Jiang N
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Jun; 28(3):332-5. PubMed ID: 21644235
[TBL] [Abstract][Full Text] [Related]
9. Prenatal screening for Down's syndrome with use of maternal serum markers.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
[TBL] [Abstract][Full Text] [Related]
10. Second trimester screening for Down's syndrome: 7 years experience.
Beaman JM; Goldie DJ
J Med Screen; 2001; 8(3):128-31. PubMed ID: 11678551
[TBL] [Abstract][Full Text] [Related]
11. Antenatal screening for Down's syndrome: where are we and where next?
Haddow JE
Lancet; 1998 Aug; 352(9125):336-7. PubMed ID: 9717914
[No Abstract] [Full Text] [Related]
12. Prevalence rate of Down's syndrome in Karachi resident women.
Rahman S; Obaid-ur-Rahman M
Pak J Pharm Sci; 2005 Apr; 18(2):61-3. PubMed ID: 16431402
[TBL] [Abstract][Full Text] [Related]
13. [Early pregnancy serum screening in Helsinki: results and mothers' opinions].
Salonen R; Turpeinen U; Kurki L; Lappalainen M; Ammälä P; Hiilesmaa V; Teramo K; von Koskull H; Gahmberg N; Stenman UH
Duodecim; 1997; 113(24):2548-55. PubMed ID: 10892162
[No Abstract] [Full Text] [Related]
14. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
Crossley JA; Aitken DA; Berry E; Connor JM
J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
[TBL] [Abstract][Full Text] [Related]
15. Screening of maternal serum for fetal Down's syndrome in the first trimester.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
[TBL] [Abstract][Full Text] [Related]
16. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
Spencer K; Crossley JA; Aitken DA; Nix AB; Dunstan FD; Williams K
Ann Clin Biochem; 2003 May; 40(Pt 3):219-31. PubMed ID: 12803832
[TBL] [Abstract][Full Text] [Related]
17. Practical strategies in contingent sequential screening for Down syndrome.
Benn P; Wright D; Cuckle H
Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
[TBL] [Abstract][Full Text] [Related]
18. The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome.
Christiansen M; Høgdall EV; Larsen SO; Høgdall C
Prenat Diagn; 2002 May; 22(5):385-7. PubMed ID: 12001192
[TBL] [Abstract][Full Text] [Related]
19. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
Wald NJ; Watt HC; Hackshaw AK
N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
[TBL] [Abstract][Full Text] [Related]
20. Maternal serum markers for Down's syndrome pregnancies.
Chew S; Anandakumar C; Ratnam SS
Singapore Med J; 1995 Aug; 36(4):417-23. PubMed ID: 8919160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
